US Patent

US12115164 — Pemetrexed formulations

Method of Use · Assigned to Eagle Pharmaceuticals Inc · Expires 2036-02-19 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects formulations of the drug pemetrexed that remain stable in a non-aqueous solvent for at least 48 hours or 24 months when stored at 2-8°C.

USPTO Abstract

The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4246 — chembl-chembl225072

Patent Metadata

Patent number
US12115164
Jurisdiction
US
Classification
Method of Use
Expires
2036-02-19
Drug substance claim
No
Drug product claim
No
Assignee
Eagle Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.